{
    "id": 3315,
    "fullName": "ERBB2 G309A",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ERBB2 (HER2) G309A lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). G309A does not result in increased Erbb2 (Her2) phosphorylation, but is transforming in cell culture and promotes tumor formation in xenograft models, and is predicted to enhance Erbb2 (Her2) dimerization in one study (PMID: 23220880), however, in another study, G309A results in similar cell proliferation and viability levels to wild-type Erbb2 (Her2) in two different cell lines in culture (PMID: 29533785), and therefore, its effect on Erbb2 (Her2) protein function is unknown.",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 1980,
                    "pubMedId": 23220880,
                    "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23220880"
                },
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2064,
        "geneSymbol": "ERBB2",
        "terms": [
            "ERBB2",
            "CD340",
            "HER-2",
            "HER-2/neu",
            "HER2",
            "MLN 19",
            "NEU",
            "NGL",
            "TKR1"
        ]
    },
    "variant": "G309A",
    "createDate": "02/24/2015",
    "updateDate": "10/22/2019",
    "referenceTranscriptCoordinates": {
        "id": 170497,
        "transcript": "NM_004448",
        "gDna": "chr17:g.39711952G>C",
        "cDna": "c.926G>C",
        "protein": "p.G309A",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2029,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) G309A demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880).",
            "molecularProfile": {
                "id": 3131,
                "profileName": "ERBB2 G309A"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1980,
                    "pubMedId": 23220880,
                    "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23220880"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2030,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human breast cell lines expressing ERBB2 G309A reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).",
            "molecularProfile": {
                "id": 3131,
                "profileName": "ERBB2 G309A"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1980,
                    "pubMedId": 23220880,
                    "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23220880"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2028,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human breast cell lines expressing ERBB2 G309A demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880).",
            "molecularProfile": {
                "id": 3131,
                "profileName": "ERBB2 G309A"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1980,
                    "pubMedId": 23220880,
                    "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23220880"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15975,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Faslodex (fulvestrant) inhibited growth of estrogen-receptor (ESR1)-positive breast cancer cells harboring ERBB2 (HER2) G309A in culture (PMID: 30314968).",
            "molecularProfile": {
                "id": 31352,
                "profileName": "ERBB2 G309A ESR1 pos"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3131,
            "profileName": "ERBB2 G309A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31352,
            "profileName": "ERBB2 G309A ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 170497,
            "transcript": "NM_004448",
            "gDna": "chr17:g.39711952G>C",
            "cDna": "c.926G>C",
            "protein": "p.G309A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 170498,
            "transcript": "NM_001289937",
            "gDna": "chr17:g.39711952G>C",
            "cDna": "c.926G>C",
            "protein": "p.G309A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}